NanoVibronix Inc. (NAOV): יחס שווי פעילות לרווח לפני ריבית, מסים ופחת
The current EV/EBITDA chart for NanoVibronix, Inc. (NAOV), which stands at 0.00, illustrates the position of the developer of ultrasonic systems for skin wound healing and pain relief. The firm's success relies on the sale of specialized patches, while management focuses on securing insurance reimbursements. The innovative wave therapy ecosystem enables the minimization of antibiotic use in catheter care.
פילוחי מדדים מקיפים ואנליטיקה עבור NanoVibronix Inc. (NAOV)
The development of therapeutic devices and the implementation of ultrasound catheters require significant capital expenditures, making the capital structure of NanoVibronix, Inc. (NAOV) sensitive to debt. The multiple compares the total enterprise value with operating profit before depreciation and amortization (EBITDA), neutralizing the impact of debt load on the valuation. By analyzing the EV/EBITDA valuation trend, an investor can identify an entry point at historical lows or detect signs of a systemic crisis.
